L3VLUP
ProSign in

VERA · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

VERAVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • VERA
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterVERAVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 2021none listed holders, n.a.35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 2022none listed holders, n.a.23 holders, $16.1bn
Q2 2022none listed holders, n.a.25 holders, $18.1bn
Q3 20221 holders, $3.6m22 holders, $18.4bn
Q4 20223 holders, $7.8m28 holders, $18.4bn
Q1 20231 holders, $14m26 holders, $21.4bn
Q2 20232 holders, $28m27 holders, $24.7bn
Q3 20231 holders, $35m33 holders, $24.3bn
Q4 20231 holders, $39m32 holders, $28.6bn
Q1 20246 holders, $185m31 holders, $29.8bn
Q2 20245 holders, $257m29 holders, $33.4bn
Q3 20246 holders, $346m27 holders, $33.5bn
Q4 20244 holders, $351m26 holders, $28.5bn
Q1 20252 holders, $77m21 holders, $35.4bn
Q2 20252 holders, $68m21 holders, $32.3bn
Q3 20253 holders, $71m22 holders, $25.9bn
Q4 20254 holders, $481m26 holders, $31.8bn
Q1 20266 holders, $299m25 holders, $31.8bn
Q2 20261 holders, $43m26 holders, $34.6bn
VERA

Vera Therapeutics Inc

Holders
6
Reported value
$299m
Buyers
18
Sellers
10

Breadth +8 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
25
Reported value
$31.8bn
Buyers
17
Sellers
21

Breadth -4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2026

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only VERA (2)

Freestone Grove Partners LP, Point72 Asset Management LP

Only VRTX (21)

Acadian Asset Management LLC, AllianceBernstein LP, Arrowstreet Capital LP, Baillie Gifford & Co, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Two Sigma Investments LP, Walleye Capital LLC, Wellington Management Group LLP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →